Biologic Therapies VII: Precision Medicine in the Biologic Era

Biologic Therapies VII: Precision Medicine in the Biologic Era

Cleveland Clinic R.J. Fasenmyer Center for Clinical Immunology presents Biologic Therapies VII: Precision Medicine in the Biologic Era , an online series brings together world leaders in immune-based therapies and addresses cutting-edge translational immunology and the latest data on biologic therapeutics.

In the Biologic Therapies VII: Precision Medicine in the Biologic Era online series, an international, multi-disciplinary faculty of experts critically appraise recent basic laboratory breakthroughs in terms of their potential clinical implications and provide in-depth analyses of approved agents, new agents, predicting toxicity, clinical controversies, and new indications.

Series Objectives

  1. Describe recent advances in biologic drug development, regulations, and indications in immune-mediated inflammatory diseases (IMIDs).
  2. Critically appraise data on genetics and personalized medicine as applied to rheumatic diseases and IMIDs.
  3. Analyze recent investigations on efficacy and toxicity of biologic agents across IMIDs.
  4. Detail current knowledge related to predicting outcomes in patients with rheumatoid arthritis (RA).
  5. Summarize updates in diagnosis, classification, therapies, and immune-system targets in both psoriatic arthritis (PsA) and spondyloarthopathies (SpA) and describe their clinical implications.
  6. Critically assess clinical data on biologic use in immune-related diseases in the areas of pulmonary disease, dermatology, metabolic bone diseases, and systemic lupus erythematosus (SLE).
  7. Develop strategies to predict, prevent, and treat comorbid complications of biologic therapy including cardiovascular disease and serious infections.

Target Audience

The online series is designed for rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, and associated allied health practitioners, including nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and inflammatory disorders.

Activity Directors

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Department of Rheumatic and Immunologic Diseases
Cleveland Clinic
Cleveland, OH

M. Elaine Husni, MD, MPH
Director, Arthritis and Musculoskeletal Treatment Center
Vice Chair, Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH